# A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)

> **NCT01074944** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 170 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** Eliglustat tartrate

## Key facts

- **NCT ID:** NCT01074944
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2017-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01074944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01074944, "A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01074944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*